J Ye, Q Wu, Q Ji, S You, S Gao, G Zhao… - Journal of …, 2024 - Taylor & Francis
Docetaxel (Doc), as a first-line chemotherapy drug for prostate cancer (PC), often loses its
therapeutic efficacy due to acquired resistance and lack of targeting specificity. Therefore …